Metronomic administration of ibandronate and its anti-angiogenic effects in vitro

Barrett, 2004, Ibandronate: a clinical pharmacological and pharmacokinetic update, J. Clin. Pharmacol., 44, 951, 10.1177/0091270004267594 Daubine, 2007, Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis, J. Natl. Cancer Inst., 99, 322, 10.1093/jnci/djk054 Ferretti, 2007, Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis, Bone, 41, 155, 10.1016/j.bone.2007.04.177 Fournier, 2002, Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats, Cancer Res., 62, 6538 Jih, 2001, Distinct regulation of genes by bFGF and VEGF-A in endothelial cells, Angiogenesis, 4, 313, 10.1023/A:1016080321956 Kuhn, 2006, Enhanced expression of VEGF following bFGF inhibition in non-small cell lung cancer cell lines, Lung Cancer, 54, 149, 10.1016/j.lungcan.2006.07.016 Leyland-Jones, 2004, Pharmacokinetic and clinical equivalence of oral and intravenous ibandronate for metastatic bone disease, European Journal of Cancer Supplements, 2, 9, 10.1016/j.ejcsup.2004.01.003 Martin, 2000, Bisphosphonates — mechanisms of action, Australian Prescriber, 23, 130, 10.18773/austprescr.2000.144 Michailidou, 2006, The effects of combined treatment using paclitaxel and zoledronic acid on tumour cells and endothelial cells in vitro, Heamatologica reports, 2, 48 Mystakidou, 2008, Oral versus intravenous ibandronic acid: a comparison of treatment options for metastatic bone disease, J. Cancer Res. Clin. Oncol., 134, 1303, 10.1007/s00432-008-0419-x Santini, 2003, Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients, Clin. Cancer Res., 9, 2893 Santini, 2007, Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients, Clin. Cancer Res., 13, 4482, 10.1158/1078-0432.CCR-07-0551 Thompson, 2006, Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis, Mol. Pharmacol., 69, 1624, 10.1124/mol.105.020776 Tsai, 1995, Vascular endothelial growth factor in human glioma cell lines: induced secretion by EGF, PDGF-BB, and bFGF, J. Neurosurg., 82, 864, 10.3171/jns.1995.82.5.0864 Vujasinovic, 2006, Angiogenesis: bFGF and VEGF in breast carcinoma, Arch. Oncol., 14, 126, 10.2298/AOO0604126V Wood, 2002, Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid, J. Pharmacol. Exp. Ther., 302, 1055, 10.1124/jpet.102.035295